参考文献

1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Thymomas and Thymic Carcinomas Version 2.2019 — March 11, 2019.

2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).

3.Marx A, Chan JK, Coindre JM, et al.The 2015 World Health Organization classification of tumors of the thymus: continuity and changes.J Thorac Oncol 2015,10: 1383-1395.

4.Zhao Y, Shi J, Fan L, et al.Surgical treatment of thymoma: an11-year experience with 761 patients.Eur J Cardiothorac Surg 2016,49: 1144-1149.

5.Yokoi K, Kondo K, Fujimoto K, et al.JLCS medical practice guidelines for thymic tumors: summary of recommendations.Jpn J Clin Oncol 2017,47: 1119-1122.

6.Carter BW, Benveniste MF, Madan R, et al.ITMIG classification of mediastinal compartments and multidisciplinary approach to mediastinal masses.Radiographics 2017,37: 413-436.(https://www.daowen.com)

7.Ruffini E, Venuta F.Management of thymic tumors: a European perspective.J ThoracDis 2014,6 Suppl 2: S228-237.

8.Lim YJ, Kim HJ, Wu HG.Role of postoperative radiotherapy in nonlocalized thymoma: propensitymatched analysis of Surveillance, Epidemiology, and End Results database.J Thorac Oncol 2015,10: 1357-1363.

9.Kanzaki R, Kanou T, Ose N, et al.Long-term outcomes of advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy followed by surgery: a 20-year experience.Interact Cardiovasc Thorac Surg 2019,28: 360-367.

10.Kumar V, Garg M, Goyal A, et al.Changing pattern of secondary cancers among patients with malignant thymoma in the USA.Future Oncol 2018,14: 1943-1951.

11.Bluthgen MV, Boutros C, Fayard F, et al.Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors(TET): A single-institution experience.Lung Cancer 2016,99: 111-116.